Cancer Family
Malignant Mesothelioma
CI-CAN-00000240Explore in graph →
Top-level96 active trials4 approved drugs11 evidence items
- NCIt
- C4456
- ICD-10
- C45
- DOID
- 1790
- MeSH
- D000086002
- MeSH
- D008654
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000240Explore in graph →
Clinical trials
478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (81)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04462809 | Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma(TALAMESO) | unknown | Phase 2 | 40 | Hospices Civils de LyonOTHER | 0 | Jul 9, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 |
| clinicaltrials |
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | unknown | Phase 2 | 27 | Hutchison Medipharma LimitedINDUSTRY | 1 | Jun 16, 2020 | clinicaltrials |
| NCT02948413 | Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials | completed | — | 55 | National Institutes of Health Clinical Center (CC)NIH | 1 | May 26, 2020 | clinicaltrials |
| NCT01112293 | Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma | completed | Phase 2 | 14 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01119664 | Combination Gene Transfer and Chemotherapy | completed | Phase 1 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02357147 | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)(ARTEMIS) | terminated | Phase 2 | 124 | MorphotekINDUSTRY | 6 | Mar 17, 2020 | clinicaltrials |
| NCT00770120 | S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery | completed | Phase 2 | 61 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2020 | clinicaltrials |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT00372840 | Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer | completed | N/A | 340 | Fox Chase Cancer CenterOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT02194231 | ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)(ATREUS) | completed | Phase 2 | 145 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2019 | clinicaltrials |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | terminated | Early Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | terminated | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03436732 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2019 | clinicaltrials |
| NCT00859469 | Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma | completed | Phase 2 | 29 | Columbia UniversityOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02040272 | Mesothelioma and Radical Surgery 2(MARS2) | unknown | N/A | 328 | Royal Brompton & Harefield NHS Foundation TrustOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT00188890 | Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers | completed | — | 1,452 | University Health Network, TorontoOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT04056026 | A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma | completed | Early Phase 1 | 1 | ProgenaBiomeOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT01098266 | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | completed | Phase 3 | 400 | AGC Biologics S.p.A.INDUSTRY | 12 | Sep 17, 2019 | clinicaltrials |
| NCT01722149 | Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | completed | Early Phase 1 | 4 | University of ZurichOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03068117 | Malignant Mesothelioma - Can we Improve Quality of Life(RESPECT-Meso) | completed | N/A | 319 | Portsmouth Hospitals NHS TrustOTHER_GOV | 2 | Jun 13, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT00334594 | Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 153 | Swiss Cancer InstituteOTHER | 2 | May 15, 2019 | clinicaltrials |
| NCT02349958 | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy(HIPEC/IPHC) | unknown | Phase 2 | 200 | Bay Area Gynecology OncologyOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03175172 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | terminated | Phase 2 | 10 | Aduro Biotech, Inc.INDUSTRY | 1 | Apr 4, 2019 | clinicaltrials |
| NCT02106559 | Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Mar 21, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT02958683 | Chest Wall Motion Analysis in Disease(CWM) | completed | — | 400 | Heart of England NHS TrustOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT00898547 | Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107 | terminated | — | 47 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jan 24, 2019 | clinicaltrials |
| NCT00484276 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma(NGR010) | completed | Phase 2 | 57 | AGC Biologics S.p.A.INDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01358084 | Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM(NGR019) | completed | Phase 2 | 137 | AGC Biologics S.p.A.INDUSTRY | 3 | Jan 15, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01592383 | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02397928 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | completed | Phase 2 | 82 | NovoCure Ltd.INDUSTRY | 7 | Sep 25, 2018 | clinicaltrials |
| NCT01445392 | SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2018 | clinicaltrials |
| NCT01776385 | The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma | completed | N/A | 9 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00458913 | Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 82 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 12, 2018 | clinicaltrials |
| NCT01126346 | Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)(HOPE) | completed | N/A | 10 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01325753 | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 3, 2018 | clinicaltrials |
| NCT03558932 | IP3R Modulation by Cancer Genes in Mesothelioma | unknown | — | 20 | KU LeuvenOTHER | 0 | Jun 15, 2018 | clinicaltrials |
| NCT00365053 | PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2018 | clinicaltrials |
| NCT02661659 | A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT01627795 | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment | suspended | Phase 1 / Phase 2 | 17 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01188486 | Pulmonary Interstitial Lymphography in Early Stage Lung Cancer | terminated | N/A | 12 | Stanford UniversityOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT02761863 | Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma | unknown | — | 100 | Ain Shams UniversityOTHER | 0 | Feb 23, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Jul 9, 2020source: clinicaltrials